Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries CNS Digital Health Company GYENNO SCIENCE Listed on The Digital Health 150, Being One of the Most Promising Digital Health Companies of 2022 Globally By: Get News February 22, 2023 at 08:24 AM EST CB Insights, a worldwide trusted business analytics platform and global database that provides market intelligence, unveiled the fourth annual Digital Health 150 — a list of 150 of the top private companies transforming healthcare with digital technology. GYENNO SCIENCE was listed to be one of the most promising digital health companies and was the only Chinese company in the category of Digital Therapeutics.The Digital Health 150 is CB Insights' annual ranking of the 150 most promising digital health startups in the world. The 150 winners were selected from a pool of over 13,000 companies based on complex factors. They were from 18 countries and were categorized into 14 groups including Digital Therapeutic, Clinical Intelligence, Clinical Trial Tech, Computer-aided Imaging, etc. In the 2021 Digital Health 150, digital therapeutics companies accounted for 11.3%, while among the global companies on the list of 2022, the proportion was only 4.7%. Its persistent focus in the field of Parkinson’s Disease, cutting-edge treatment and patient management concepts, world-leading digital health technology are the reasons why GYENNO SCIENCE makes the list.Founded in 2013, GYENNO SCIENCE chose Parkinson's Disease as the entry point of the CNS disease market. With a 10 years accumulative effort of technology research and development, it has built a all-time-and-space diagnosis and treatment system based on advanced technology, and provided innovative value for patients, clinical experts and industrial partners in this field. As of 2022, several digital diagnosis and treatment products developed by GYENNO SCIENCE have been approved by the EU CE certification and the US FDA certification. The listing of Digital Health 150 is a global recognition of its vision and technology innovation.About Digital Health 150 selection factors:The selection factors of Digital Health 150 include patents, investor profile, proprietary Mosaic score, market potential, business relationships, competitive landscape, team strength, and tech novelty. The Mosaic Score is based on CB Insights' algorithm, measures the overall health and growth potential of private companies to help predict a company's momentum.Media ContactCompany Name: GYENNO SCIENCEContact Person: Hayes ChenEmail: Send EmailCountry: ChinaWebsite: https://www-dev.gyenno.com/ Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
CNS Digital Health Company GYENNO SCIENCE Listed on The Digital Health 150, Being One of the Most Promising Digital Health Companies of 2022 Globally By: Get News February 22, 2023 at 08:24 AM EST CB Insights, a worldwide trusted business analytics platform and global database that provides market intelligence, unveiled the fourth annual Digital Health 150 — a list of 150 of the top private companies transforming healthcare with digital technology. GYENNO SCIENCE was listed to be one of the most promising digital health companies and was the only Chinese company in the category of Digital Therapeutics.The Digital Health 150 is CB Insights' annual ranking of the 150 most promising digital health startups in the world. The 150 winners were selected from a pool of over 13,000 companies based on complex factors. They were from 18 countries and were categorized into 14 groups including Digital Therapeutic, Clinical Intelligence, Clinical Trial Tech, Computer-aided Imaging, etc. In the 2021 Digital Health 150, digital therapeutics companies accounted for 11.3%, while among the global companies on the list of 2022, the proportion was only 4.7%. Its persistent focus in the field of Parkinson’s Disease, cutting-edge treatment and patient management concepts, world-leading digital health technology are the reasons why GYENNO SCIENCE makes the list.Founded in 2013, GYENNO SCIENCE chose Parkinson's Disease as the entry point of the CNS disease market. With a 10 years accumulative effort of technology research and development, it has built a all-time-and-space diagnosis and treatment system based on advanced technology, and provided innovative value for patients, clinical experts and industrial partners in this field. As of 2022, several digital diagnosis and treatment products developed by GYENNO SCIENCE have been approved by the EU CE certification and the US FDA certification. The listing of Digital Health 150 is a global recognition of its vision and technology innovation.About Digital Health 150 selection factors:The selection factors of Digital Health 150 include patents, investor profile, proprietary Mosaic score, market potential, business relationships, competitive landscape, team strength, and tech novelty. The Mosaic Score is based on CB Insights' algorithm, measures the overall health and growth potential of private companies to help predict a company's momentum.Media ContactCompany Name: GYENNO SCIENCEContact Person: Hayes ChenEmail: Send EmailCountry: ChinaWebsite: https://www-dev.gyenno.com/